Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025 17:00 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025 17:00 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…